Last updated: February 22, 2026
What is the Generic Name and Indication for NDC 50742-0388?
NDC 50742-0388 corresponds to Blenrep (belantamab mafodotin-blmf), a monoclonal antibody-derived drug approved for the treatment of relapsed or refractory multiple myeloma. It specifically targets B-cell maturation antigen (BCMA).
Market Landscape
Segment Overview
- Therapeutic Area: Multiple myeloma
- Indication: Relapsed/refractory cases, often in patients previously treated with proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies.
- Market Size: The global multiple myeloma treatment market was valued at approximately USD 8.3 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 8% through 2027, reaching an estimated USD 12 billion.
Key Competitors
| Drug Name |
MOA |
Approval Year |
Indications |
Market Share (2022) |
| Carfilzomib (Kyprolis) |
Proteasome inhibitor |
2015 |
Multiple myeloma |
20% |
| Daratumumab (Darzalex) |
Anti-CD38 monoclonal antibody |
2015 |
Multiple myeloma |
35% |
| Isatuximab (Sarclisa) |
Anti-CD38 monoclonal antibody |
2020 |
Multiple myeloma |
7% |
| Belantamab mafodotin |
BCMA-targeted monoclonal antibody-drug conjugate |
2020 |
Relapsed/refractory multiple myeloma |
10% (estimated) |
Clinical and Commercial Development
Belantamab mafodotin received accelerated approval from the FDA in 2020. Subsequent trials assess combination therapies and expanded indications. Despite competition, its unique mechanism and targeted approach sustain market relevance, particularly in late-line treatment.
Price Projections
Current Pricing
- List price per 2.5 mg/vial: approximately USD 8,600.
- Typical dosage: 2.5 mg/kg every three weeks, with an average patient weight of 70 kg.
| Price Aspect |
Figures |
| Per dose (based on 70 kg patient) |
USD 55,250 |
| Cost per cycle (4 doses) |
USD 221,000 |
| Annual treatment cost (estimated) |
USD 660,000 |
Pricing Trends and Factors
- Price Adjustments: The list price remains relatively stable but could decline due to biosimilar or generic entrants if patents expire.
- Payer Discounts: Negotiated rebates and discounts reduce net prices, typically by 20-30%.
- Market Penetration: High costs restrict earlier-line adoption, concentrating sales in late-line settings.
Future Price Projections (2023–2027)
| Year |
Estimated List Price (USD per vial) |
Rationale |
| 2023 |
USD 8,600 |
Base case, no significant price change |
| 2024 |
USD 8,600 |
Patent exclusivity maintains prices |
| 2025 |
USD 7,700–8,100 |
Potential price erosion from biosimilars, rebates, and market competition |
| 2026 |
USD 7,000–7,500 |
Increased biosimilar presence, market pressures |
| 2027 |
USD 6,500–7,000 |
Entry of biosimilar competitors, negotiations |
Impact of Biosimilars and Market Dynamics
Patent expiration for biologics typically occurs 12 years from FDA approval. If belantamab mafodotin's patents expire around 2032, biosimilar entry could start around 2034, potentially cutting prices by 30-50%. Currently, no biosimilar is marketed.
Reimbursement and Cost-Effectiveness Considerations
Government programs and private insurers prioritize value-based contracts. Cost-effectiveness analyses position belantamab mafodotin at high costs relative to clinical benefit, influencing future pricing negotiations.
Regulatory and Policy Influences
- FDA: Approval pathways for biosimilars could expedite competitive entry.
- CMS Policies: Price negotiations and caps under Medicare could lower future reimbursement rates.
- Orphan Drug Designation: Limited impact on pricing, but grants some exclusivity.
Key Takeaways
- The drug's market is constrained by high pricing, competing therapies, and potential biosimilar entry.
- Current list prices estimate USD 8,600 per vial, with annual treatment costs near USD 660,000.
- Market growth driven by increased use in late-line multiple myeloma exceeds USD 8 billion globally, with annual growth around 8%.
- Future pricing is likely to decline by approximately 20-30% within five years due to biosimilar competition and market pressures.
- Pricing negotiations, reimbursement policies, and clinical adoption significantly influence net revenue.
FAQs
1. When are biosimilars for belantamab mafodotin expected?
Biosimilars could enter the market around 2034, assuming patent expiration around 2032.
2. How does belantamab mafodotin compare with other BCMA-targeted therapies?
Belantamab is a monotherapy antibody-drug conjugate; newer therapies include CAR-T cells and bispecific antibodies, offering differing administration routes, efficacy, and safety profiles.
3. What factors could accelerate price declines?
Patent expiry, biosimilar approval, payer negotiations, and market competition. Additionally, clinical trial outcomes that expand indications might influence pricing dynamics.
4. Is there potential for off-label or expanded use?
Yes, ongoing trials explore combination regimens and broader indications, which could influence demand and pricing strategies.
5. How does the treatment cost impact adoption?
High costs limit early-line use; payers favor later-line, high-need populations. Value-based reimbursement models could further restrict utilization or negotiate lower prices.
References
[1] MarketWatch. (2022). Global multiple myeloma market size & trends.
[2] FDA. (2020). Belantamab mafodotin-blmf approval letter.
[3] IBISWorld. (2022). Biotech and pharmaceutical markets overview.
[4] EvaluatePharma. (2023). Oncology drug pricing and trends.
[5] Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for biologics.
